Abstract
Nucleic acid therapeutics has huge potential for the treatment of a wide range of diseases including respiratory diseases. Plasmid DNA (pDNA) and small interfering RNA (siRNA) are the two most widely investigated nucleic acids for therapeutic development. However, efficient and safe delivery of nucleic acids is still a major hurdle in translating nucleic acid therapy into clinical practice. For the treatment of respiratory diseases, administration via inhalation is the most direct and effective way to deliver therapeutic nucleic acids to the lungs. Although liquid aerosol formulation is investigated in most of the studies, it is not desirable in terms of maintaining the stability of nucleic acid especially during long-term storage. This problem could be circumvented by formulating the therapeutic nucleic acids into dry powder for inhalation, and should be considered as the future direction of developing inhalable nucleic acids. In this review, the three major particle engineering methods investigated for the preparation of inhalable pDNA and siRNA formulations, including spray drying (SD), spray freeze drying (SFD) and supercritical fluid (SFC) drying, are discussed and compared. Moreover, common assessment methods and the challenges of evaluating the biological activities of inhalable nucleic acid powders are also reviewed.
Keywords: Dry powder, pulmonary delivery, DNA, siRNA, spray drying, spray freeze drying, supercritical fluid.
Current Pharmaceutical Design
Title:Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Volume: 21 Issue: 27
Author(s): Michael Y.T. Chow and Jenny K.W. Lam
Affiliation:
Keywords: Dry powder, pulmonary delivery, DNA, siRNA, spray drying, spray freeze drying, supercritical fluid.
Abstract: Nucleic acid therapeutics has huge potential for the treatment of a wide range of diseases including respiratory diseases. Plasmid DNA (pDNA) and small interfering RNA (siRNA) are the two most widely investigated nucleic acids for therapeutic development. However, efficient and safe delivery of nucleic acids is still a major hurdle in translating nucleic acid therapy into clinical practice. For the treatment of respiratory diseases, administration via inhalation is the most direct and effective way to deliver therapeutic nucleic acids to the lungs. Although liquid aerosol formulation is investigated in most of the studies, it is not desirable in terms of maintaining the stability of nucleic acid especially during long-term storage. This problem could be circumvented by formulating the therapeutic nucleic acids into dry powder for inhalation, and should be considered as the future direction of developing inhalable nucleic acids. In this review, the three major particle engineering methods investigated for the preparation of inhalable pDNA and siRNA formulations, including spray drying (SD), spray freeze drying (SFD) and supercritical fluid (SFC) drying, are discussed and compared. Moreover, common assessment methods and the challenges of evaluating the biological activities of inhalable nucleic acid powders are also reviewed.
Export Options
About this article
Cite this article as:
Chow Y.T. Michael and Lam K.W. Jenny, Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation, Current Pharmaceutical Design 2015; 21 (27) . https://dx.doi.org/10.2174/1381612821666150820105916
DOI https://dx.doi.org/10.2174/1381612821666150820105916 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Cyclooxygenase-2 Inhibitors: A Painful Lesson
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Approaches for Imaging the Diabetic Pancreas: First Results
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Curcumin Targets Circulating Cancer Stem Cells by Inhibiting Self-Renewal Efficacy in Non-Small Cell Lung Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules
Current Drug Metabolism New Ketonethiosemicarbazones for Melanogenesis Inhibition
Current Bioactive Compounds Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer
Current Medicinal Chemistry Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a Trend in Both Cancer Gene Therapy and Cancer Virotherapy
Current Pharmaceutical Biotechnology Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets Neuropeptides as Autocrine Growth Factors in Cancer Cells
Current Pharmaceutical Design